<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02394145</url>
  </required_header>
  <id_info>
    <org_study_id>PIANO-genetics</org_study_id>
    <nct_id>NCT02394145</nct_id>
  </id_info>
  <brief_title>Genotype and Platelet Reactivity in Patients on Hemodialysis</brief_title>
  <official_title>The Relationship Between Genotype and Platelet Reactivity in Patients Treated With Ticagrelor Versus Clopidogrel: PIANO Genotype Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kyunghee University Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Kyunghee University Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Patients with end stage renal disease (ESRD) on hemodialysis (HD) exhibited higher platelet
      reactivity to clopidogrel than did those with normal renal function. We recently reported
      platelet inhibition by ticagrelor was faster and markedly greater than by clopidogrel with
      onset dosing regimen in patients with ESRD on HD. However, few studies have been conducted
      genetic influence in high platelet reactivity in patients with ESRD on HD.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Chronic kidney disease (CKD) is a strong risk factor for cardiovascular morbidity and
      mortality, and confers an increasing risk of stent thrombosis even when dual antiplatelet
      therapy (clopidogrel and aspirin) is administered. Patients with severe CKD or end stage
      renal disease (ESRD) on hemodialysis (HD) exhibited higher platelet reactivity to clopidogrel
      than did those with normal renal function. We recently reported platelet inhibition by
      ticagrelor was markedly greater than by clopidogrel in patients with ESRD on HD. But exact
      mechanism of high platelet reactivity in ESRD patients was not fully evaluated. A possible
      postulation would be genetic influence. To investigate this issue, we will evaluate genetic
      polymorphism in patients with normal kidney function and ESRD on HD according to different
      doses of clopidogrel and ticagrelor. Genetic test will be assessed polymorphism of ABCB1,
      PON1, CYP2C19, CYP2C9 and P2Y12.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>September 2009</start_date>
  <completion_date type="Anticipated">August 2015</completion_date>
  <primary_completion_date type="Anticipated">August 2015</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The difference of antiplatelet effects according to genotype</measure>
    <time_frame>14 days after study drug treatment</time_frame>
    <description>The difference of P2Y12 reaction units (PRUs) according to genotype</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The difference of antiplatelet effects according to kidney function</measure>
    <time_frame>14 days after study drug treatment</time_frame>
    <description>The difference of P2Y12 reaction units (PRUs) according to kidney function</description>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Chronic Kidney Disease</condition>
  <arm_group>
    <arm_group_label>Ticagrelor 180mg in ESRD patients</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>After randomization, ESRD patients on HD will be treated by an initial loading dose of ticagrelor (180 mg) and maintenance doses (ticagrelor 90 mg twice daily) for 14 days. Platelet reactivity and genetic polymorphism will be assessed.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Clopidogrel 75mg in ESRD patients</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>After randomization, ESRD patients on HD will be treated by an initial loading dose of clopidogrel 300 mg) and maintenance doses (clopidogrel 75 mg once a day) for 14 days. Platelet reactivity and genetic polymorphism will be assessed.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Clopidogrel 150mg in ESRD patients</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>After randomization, ESRD patients on HD will be treated by an initial loading dose of clopidogrel 300 mg) and maintenance doses (clopidogrel 150 mg once a day) for 14 days. Platelet reactivity and genetic polymorphism will be assessed.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ticagrelor 180mg in normal kidney</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>After randomization, patients with normal kidney function will be treated by an initial loading dose of ticagrelor (180 mg) and maintenance doses (ticagrelor 90 mg twice daily) for 14 days. Platelet reactivity and genetic polymorphism will be assessed</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Clopidogrel 75mg in normal kidney</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>After randomization, patients with normal kidney function will be treated by an initial loading dose of clopidogrel 300 mg) and maintenance doses (clopidogrel 75 mg once a day) for 14 days. Platelet reactivity and genetic polymorphism will be assessed.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ticagrelor</intervention_name>
    <description>Patients with normal kidney function and ESRD on hemodialysis will be treated by ticagrelor 90mg twice a day for 14 days. After then, platelet reactivity will be assessed by light aggregometry and VerifyNow assay.</description>
    <arm_group_label>Ticagrelor 180mg in ESRD patients</arm_group_label>
    <arm_group_label>Ticagrelor 180mg in normal kidney</arm_group_label>
    <other_name>Brilinta</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Clopidogrel</intervention_name>
    <description>Patients with normal kidney function and ESRD on hemodialysis will be treated by clopidogrel 75mg or 150mg once a day for 14 days. After then, platelet reactivity will be assessed by light aggregometry and VerifyNow assay.</description>
    <arm_group_label>Clopidogrel 75mg in ESRD patients</arm_group_label>
    <arm_group_label>Clopidogrel 150mg in ESRD patients</arm_group_label>
    <arm_group_label>Clopidogrel 75mg in normal kidney</arm_group_label>
    <other_name>Plavix</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  ESRD patients undergoing regular (≥ 6 months) maintenance HD

          -  Matching patients with normal kidney function

          -  documented coronary artery disease or high risk (Framingham heart risk score ≥ 20%) of
             coronary artery disease

        Exclusion Criteria:

          -  known allergies to aspirin, clopidogrel, or ticagrelor

          -  concomitant use of other antithrombotic drugs (oral anticoagulants, dipyridamole)

          -  thrombocytopenia (platelet count &lt;100,000/mm3)

          -  hematocrit &lt;25%

          -  uncontrolled hyperglycemia (hemoglobin A1c &gt;10%)

          -  liver disease (bilirubin level &gt;2 mg/dl)

          -  symptomatic severe pulmonary disease

          -  active bleeding or bleeding diathesis

          -  gastrointestinal bleeding within the last 6 months

          -  hemodynamic instability

          -  acute coronary or cerebrovascular event within the last 3 months

          -  pregnancy

          -  any malignancy

          -  concomitant use of a cytochrome P450 inhibitor or nonsteroidal anti-inflammatory drug

          -  recent treatment (&lt;30 days) with a glycoprotein IIb/IIIa antagonist
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Weon Kim, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Kyung Hee University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Weon Kim, MD, PhD</last_name>
    <phone>82-2-958-8170</phone>
    <email>mylovekw@hanmail.net</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jong Shin Woo, MD, PhD</last_name>
    <phone>82-2-958-8176</phone>
    <email>snowball77@hanmail.net</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Kyung Hee University Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>130-872</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Weon Kim, MD, PhD</last_name>
      <phone>2-958-8170</phone>
      <phone_ext>82</phone_ext>
      <email>mylovekw@hanmail.net</email>
    </contact>
    <contact_backup>
      <last_name>Jong Shin Woo, MD</last_name>
      <phone>2-958-8176</phone>
      <phone_ext>82</phone_ext>
      <email>snowball77@hanmail.net</email>
    </contact_backup>
    <investigator>
      <last_name>Jong Shin Woo, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>March 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 14, 2015</study_first_submitted>
  <study_first_submitted_qc>March 19, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 20, 2015</study_first_posted>
  <last_update_submitted>March 19, 2015</last_update_submitted>
  <last_update_submitted_qc>March 19, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 20, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Kyunghee University Medical Center</investigator_affiliation>
    <investigator_full_name>Weon Kim</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>platelet</keyword>
  <keyword>ticagrelor</keyword>
  <keyword>clopidogrel</keyword>
  <keyword>end stage renal disease</keyword>
  <keyword>hemodialysis</keyword>
  <keyword>genetics</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Renal Insufficiency, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Clopidogrel</mesh_term>
    <mesh_term>Ticlopidine</mesh_term>
    <mesh_term>Ticagrelor</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

